Severe Delayed Cutaneous and Systemic Reactions to Drugs: A Global Perspective on the Science and Art of Current Practice

Kinch, 2014, An overview of FDA-approved new molecular entities: 1827-2013, Drug Discov Today, 19, 1033, 10.1016/j.drudis.2014.03.018 Kongkaew, 2008, Hospital admissions associated with adverse drug reactions: a systematic review of prospective observational studies, Ann Pharmacother, 42, 1017, 10.1345/aph.1L037 Smyth, 2012, Adverse drug reactions in children—a systematic review, PLoS One, 7, e24061, 10.1371/journal.pone.0024061 Lehloenya, 2016, Diagnostic patch testing following tuberculosis-associated cutaneous adverse drug reactions induces systemic reactions in HIV-infected persons, Br J Dermatol, 175, 150, 10.1111/bjd.14492 Phillips, 2016, Classifying ADRs–does dose matter?, Br J Clin Pharmacol, 81, 10, 10.1111/bcp.12749 Mockenhaupt, 2012, Epidemiology of cutaneous adverse drug reactions, Chem Immunol Allergy, 97, 1, 10.1159/000335612 Huang, 2011, Cutaneous adverse drug reactions in a hospital-based Chinese population, Clin Exp Dermatol, 36, 135, 10.1111/j.1365-2230.2010.03922.x Eluwa, 2012, Adverse drug reactions to antiretroviral therapy (ARVs): incidence, type and risk factors in Nigeria, BMC Clin Pharmacol, 12, 7, 10.1186/1472-6904-12-7 Coopman, 1993, Cutaneous disease and drug reactions in HIV infection, N Engl J Med, 328, 1670, 10.1056/NEJM199306103282304 Sun, 2014, Stevens-Johnson syndrome and toxic epidermal necrolysis: a multi-aspect comparative 7-year study from the People's Republic of China, Drug Des Devel Ther, 8, 2539, 10.2147/DDDT.S71736 Su, 2014, Severe cutaneous adverse reactions in a local hospital setting: a 5-year retrospective study, Int J Dermatol, 53, 1339, 10.1111/ijd.12118 Lehloenya, 2014, Clinical presentations of severe cutaneous drug reactions in HIV-infected Africans, Dermatol Clin, 32, 227, 10.1016/j.det.2013.11.004 Dodiuk-Gad, 2014, Epidemiology of severe drug hypersensitivity, Semin Cutan Med Surg, 33, 2, 10.12788/j.sder.0057 Patel, 2013, A systematic review of the drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Indian population, Indian J Dermatol Venereol Leprol, 79, 389, 10.4103/0378-6323.110749 Ding, 2010, Cutaneous adverse drug reactions seen in a tertiary hospital in Johor, Malaysia, Int J Dermatol, 49, 834, 10.1111/j.1365-4632.2010.04481.x Li, 2006, Epidemiological study of severe cutaneous adverse drug reactions in a city district of China, Clin Exp Dermatol, 31, 642, 10.1111/j.1365-2230.2006.02185.x Mockenhaupt, 2008, Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study, J Invest Dermatol, 128, 35, 10.1038/sj.jid.5701033 Mittmann, 2012, Incidence of toxic epidermal necrolysis and Stevens-Johnson syndrome in an HIV cohort: an observational, retrospective case series study, Am J Clin Dermatol, 13, 49, 10.2165/11593240-000000000-00000 Pavlos, 2014, Fever, rash, and systemic symptoms: understanding the role of virus and HLA in severe cutaneous drug allergy, J Allergy Clin Immunol Pract, 2, 21, 10.1016/j.jaip.2013.11.005 Cacoub, 2011, The DRESS syndrome: a literature review, Am J Med, 124, 588, 10.1016/j.amjmed.2011.01.017 Sidoroff, 2007, Risk factors for acute generalized exanthematous pustulosis (AGEP)—results of a multinational case-control study (EuroSCAR), Br J Dermatol, 157, 989, 10.1111/j.1365-2133.2007.08156.x Lipowicz, 2013, Prognosis of generalized bullous fixed drug eruption: comparison with Stevens-Johnson syndrome and toxic epidermal necrolysis, Br J Dermatol, 168, 726, 10.1111/bjd.12133 Brahimi, 2010, A three-year-analysis of fixed drug eruptions in hospital settings in France, Eur J Dermatol, 20, 461, 10.1684/ejd.2010.0980 Ramasamy, 2013, Allopurinol hypersensitivity: a systematic review of all published cases, 1950-2012, Drug Saf, 36, 953, 10.1007/s40264-013-0084-0 Halevy, 2008, Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel, J Am Acad Dermatol, 58, 25, 10.1016/j.jaad.2007.08.036 Aceti, 2015, Pharmacogenetics as a tool to tailor antiretroviral therapy: a review, World J Virol, 4, 198, 10.5501/wjv.v4.i3.198 Lehloenya, 2012, Cutaneous adverse drug reactions to anti-tuberculosis drugs: state of the art and into the future, Expert Rev Anti Infect Ther, 10, 475, 10.1586/eri.12.13 Rosen, 2014, Life-threatening dermatologic adverse events in oncology, Anti-cancer Drugs, 25, 225, 10.1097/CAD.0000000000000032 Ziemer, 2012, Stevens-Johnson syndrome and toxic epidermal necrolysis in patients with lupus erythematosus: a descriptive study of 17 cases from a national registry and review of the literature, Br J Dermatol, 166, 575, 10.1111/j.1365-2133.2011.10705.x Mockenhaupt, 2011, The current understanding of Stevens-Johnson syndrome and toxic epidermal necrolysis, Exp Rev Clin Immunol, 7, 803, 10.1586/eci.11.66 Bigby, 2001, Rates of cutaneous reactions to drugs, Arch Dermatol, 137, 765 Brauer, 2009, Lichenoid drug eruption, Dermatol Online J, 15, 13, 10.5070/D335C1029X Bastuji-Garin, 1993, Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme, Arch Dermatol, 129, 92, 10.1001/archderm.1993.01680220104023 Roujeau, 1997, Stevens-Johnson syndrome and toxic epidermal necrolysis are severity variants of the same disease which differs from erythema multiforme, J Dermatol, 24, 726, 10.1111/j.1346-8138.1997.tb02524.x Roujeau, 1994, The spectrum of Stevens-Johnson syndrome and toxic epidermal necrolysis: a clinical classification, J Invest Dermatol, 102, 28S, 10.1111/1523-1747.ep12388434 Sekula, 2013, Comprehensive survival analysis of a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis, J Invest Dermatol, 133, 1197, 10.1038/jid.2012.510 Gomez-Criado, 2004, Stevens-Johnson syndrome, toxic epidermal necrolysis and phenytoin: factors linked to a higher risk [in Spanish], Rev Neurol, 38, 1056 Kardaun, 2013, Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study, Br J Dermatol, 169, 1071, 10.1111/bjd.12501 Kardaun, 2007, Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist?, Br J Dermatol, 156, 609, 10.1111/j.1365-2133.2006.07704.x Cho, 2014, Generalized bullous fixed drug eruption is distinct from Stevens-Johnson syndrome/toxic epidermal necrolysis by immunohistopathological features, J Am Acad Dermatol, 70, 539, 10.1016/j.jaad.2013.11.015 Korkij, 1984, Fixed drug eruption: a brief review, Arch Dermatol, 120, 520, 10.1001/archderm.1984.01650400102024 Baird, 1988, Widespread bullous fixed drug eruption mimicking toxic epidermal necrolysis, Int J Dermatol, 27, 170, 10.1111/j.1365-4362.1988.tb04923.x Sidoroff, 2001, Acute generalized exanthematous pustulosis (AGEP)–a clinical reaction pattern, J Cutan Pathol, 28, 113, 10.1034/j.1600-0560.2001.028003113.x Hotz, 2013, Systemic involvement of acute generalized exanthematous pustulosis: a retrospective study on 58 patients, Br J Dermatol, 169, 1223, 10.1111/bjd.12502 Roujeau, 1991, Acute generalized exanthematous pustulosis: analysis of 63 cases, Arch Dermatol, 127, 1333, 10.1001/archderm.1991.01680080069004 Halevy, 2010, The spectrum of histopathological features in acute generalized exanthematous pustulosis: a study of 102 cases, Br J Dermatol, 163, 1245, 10.1111/j.1365-2133.2010.09967.x Apisarnthanarak, 2009, Serum sickness-like reaction associated with inactivated influenza vaccination among Thai health care personnel: risk factors and outcomes, Clin Infect Dis, 49, e18, 10.1086/599615 Kunnamo, 1986, Serum-sickness-like disease is a common cause of acute arthritis in children, Acta Paediatr Scand, 75, 964, 10.1111/j.1651-2227.1986.tb10324.x Zhang, 2013, HLA-B*13:01 and the dapsone hypersensitivity syndrome, N Engl J Med, 369, 1620, 10.1056/NEJMoa1213096 Lawley, 1984, A prospective clinical and immunologic analysis of patients with serum sickness, N Engl J Med, 311, 1407, 10.1056/NEJM198411293112204 Bielory, 1985, Cutaneous manifestations of serum sickness in patients receiving antithymocyte globulin, J Am Acad Dermatol, 13, 411, 10.1016/S0190-9622(85)70182-X Zhang, 2013, Intestinal mucosal permeability of children with cefaclor-associated serum sickness-like reactions, Eur J Pediatr, 172, 537, 10.1007/s00431-012-1926-y ten Holder, 2002, Cutaneous and systemic manifestations of drug-induced vasculitis, Ann Pharmacother, 36, 130, 10.1345/1542-6270(2002)036<0130:CASMOD>2.0.CO;2 Radić, 2011, Drug-induced vasculitis, 275 Mallal, 2002, Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir, Lancet (London, England), 359, 727, 10.1016/S0140-6736(02)07873-X Hetherington, 2002, Genetic variations in HLA-B region and hypersensitivity reactions to abacavir, Lancet (London, England), 359, 1121, 10.1016/S0140-6736(02)08158-8 Hung, 2005, HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol, Proc Natl Acad Sci U S A, 102, 4134, 10.1073/pnas.0409500102 Chung, 2004, Medical genetics: a marker for Stevens-Johnson syndrome, Nature, 428, 486, 10.1038/428486a Garcia-Doval, 2000, Toxic epidermal necrolysis and Stevens-Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death?, Arch Dermatol, 136, 323, 10.1001/archderm.136.3.323 Leyva, 2000, Anticonvulsant-induced toxic epidermal necrolysis: monitoring the immunologic response, J Allergy Clin Immunol, 105, 157, 10.1016/S0091-6749(00)90191-X Nassif, 2004, Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells, J Allergy Clin Immunol, 114, 1209, 10.1016/j.jaci.2004.07.047 Nassif, 2002, Drug specific cytotoxic T-cells in the skin lesions of a patient with toxic epidermal necrolysis, J Invest Dermatol, 118, 728, 10.1046/j.1523-1747.2002.01622.x Schnyder, 1997, Direct, MHC-dependent presentation of the drug sulfamethoxazole to human alphabeta T cell clones, J Clin Invest, 100, 136, 10.1172/JCI119505 Chessman, 2008, Human leukocyte antigen class I-restricted activation of CD8+ T cells provides the immunogenetic basis of a systemic drug hypersensitivity, Immunity, 28, 822, 10.1016/j.immuni.2008.04.020 Naisbitt, 2003, Characterization of drug-specific T cells in lamotrigine hypersensitivity, J Allergy Clin Immunol, 111, 1393, 10.1067/mai.2003.1507 Wei, 2012, A recent update of pharmacogenomics in drug-induced severe skin reactions, Drug Metab Pharmacokinet, 27, 132, 10.2133/dmpk.DMPK-11-RV-116 Lucas, 2015, Abacavir-reactive memory T cells are present in drug naive individuals, PLoS One, 10, e0117160, 10.1371/journal.pone.0117160 Pichler, 2002, Deciphering the immune pathomechanism of cutaneous drug reactions, Allergy, 57, 34, 10.1034/j.1398-9995.57.s72.15.x Pichler, 2003, Delayed drug hypersensitivity reactions, Ann Intern Med, 139, 683, 10.7326/0003-4819-139-8-200310210-00012 Pichler, 2006, Pharmacological interaction of drugs with immune receptors: the p-i concept, Allergol Int, 55, 17, 10.2332/allergolint.55.17 Ostrov, 2012, Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire, Proc Natl Acad Sci U S A, 109, 9959, 10.1073/pnas.1207934109 Illing, 2012, Immune self-reactivity triggered by drug-modified HLA-peptide repertoire, Nature, 486, 554, 10.1038/nature11147 Le Cleach, 2000, Blister fluid T lymphocytes during toxic epidermal necrolysis are functional cytotoxic cells which express human natural killer (NK) inhibitory receptors, Clin Exp Immunol, 119, 225, 10.1046/j.1365-2249.2000.01119.x Chung, 2015, Insights into the poor prognosis of allopurinol-induced severe cutaneous adverse reactions: the impact of renal insufficiency, high plasma levels of oxypurinol and granulysin, Ann Rheum Dis, 74, 2157, 10.1136/annrheumdis-2014-205577 Chung, 2008, Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis, Nat Med, 14, 1343, 10.1038/nm.1884 Ko, 2011, Shared and restricted T-cell receptor use is crucial for carbamazepine-induced Stevens-Johnson syndrome, J Allergy Clin Immunol, 128, 1266, 10.1016/j.jaci.2011.08.013 Chung, 2015, Oxypurinol-specific T cells possess preferential TCR clonotypes and express granulysin in allopurinol-induced severe cutaneous adverse reactions, J Investig Dermatol, 135, 2237, 10.1038/jid.2015.165 Morito, 2014, Increased ratio of FoxP3+ regulatory T cells/CD3+ T cells in skin lesions in drug-induced hypersensitivity syndrome/drug rash with eosinophilia and systemic symptoms, Clin Exp Dermatol, 39, 284, 10.1111/ced.12246 Shiohara, 2015, Crucial role of viral reactivation in the development of severe drug eruptions: a comprehensive review, Clin Rev Allergy Immunol, 49, 192, 10.1007/s12016-014-8421-3 Takahashi, 2009, Defective regulatory T cells in patients with severe drug eruptions: timing of the dysfunction is associated with the pathological phenotype and outcome, J Immunol, 182, 8071, 10.4049/jimmunol.0804002 Picard, 2010, Drug reaction with eosinophilia and systemic symptoms (DRESS): a multiorgan antiviral T cell response, Sci Transl Med, 2, 46ra62, 10.1126/scitranslmed.3001116 Shiohara, 2012, Drug-induced hypersensitivity syndrome: recent advances in the diagnosis, pathogenesis and management, Chem Immunol Allergy, 97, 122, 10.1159/000335624 Naranjo, 1981, A method for estimating the probability of adverse drug reactions, Clin Pharmacol Ther, 30, 239, 10.1038/clpt.1981.154 Sassolas, 2010, ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson syndrome and toxic epidermal necrolysis: comparison with case-control analysis, Clin Pharmacol Ther, 88, 60, 10.1038/clpt.2009.252 Saag, 2008, High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients, Clin Infect Dis, 46, 1111, 10.1086/529382 Mallal, 2008, HLA-B*5701 screening for hypersensitivity to abacavir, N Engl J Med, 358, 568, 10.1056/NEJMoa0706135 Shear, 2008, A review of drug patch testing and implications for HIV clinicians, AIDS (London, England), 22, 999, 10.1097/QAD.0b013e3282f7cb60 Phillips, 2002, Utility of patch testing in patients with hypersensitivity syndromes associated with abacavir, AIDS (London, England), 16, 2223, 10.1097/00002030-200211080-00017 Phillips, 2005, Clinical and immunogenetic correlates of abacavir hypersensitivity, AIDS (London, England), 19, 979, 10.1097/01.aids.0000171414.99409.fb Lin, 2013, A patch testing and cross-sensitivity study of carbamazepine-induced severe cutaneous adverse drug reactions, J Eur Acad Dermatol Venereol, 27, 356, 10.1111/j.1468-3083.2011.04418.x Barbaud, 2013, A multicentre study to determine the value and safety of drug patch tests for the three main classes of severe cutaneous adverse drug reactions, Br J Dermatol, 168, 555, 10.1111/bjd.12125 Waton, 2009, Negative predictive value of drug skin tests in investigating cutaneous adverse drug reactions, Br J Dermatol, 160, 786, 10.1111/j.1365-2133.2008.08975.x Rive, 2013, Testing for drug hypersensitivity syndromes, Clin Biochem Rev, 34, 15 Keane, 2014, HLA class I restricted CD8+ and class II restricted CD4+ T cells are implicated in the pathogenesis of nevirapine hypersensitivity, AIDS (London, England), 28, 1891, 10.1097/QAD.0000000000000345 Porebski, 2013, In vitro drug causality assessment in Stevens-Johnson syndrome—alternatives for lymphocyte transformation test, Clin Exp Allergy, 43, 1027, 10.1111/cea.12145 Bernstein, 2008, Allergy diagnostic testing: an updated practice parameter, Ann Allergy Asthma Immunol, 100, S1 Aberer, 2003, Drug provocation testing in the diagnosis of drug hypersensitivity reactions: general considerations, Allergy, 58, 854, 10.1034/j.1398-9995.2003.00279.x Gomes, 2016, Drug hypersensitivity in children: report from the pediatric task force of the EAACI Drug Allergy Interest Group, Allergy, 71, 149, 10.1111/all.12774 Todd, 2006, Adverse cutaneous drug eruptions and HIV: a clinician's global perspective, Dermatol Clin, 24, 459, 10.1016/j.det.2006.06.008 Lehloenya, 2011, Outcomes of reintroducing anti-tuberculosis drugs following cutaneous adverse drug reactions, Int J Tuberc Lung Dis, 15, 1649, 10.5588/ijtld.10.0698 White, 2015, Evolving models of the immunopathogenesis of T cell-mediated drug allergy: the role of host, pathogens, and drug response, J Allergy Clin Immunol, 136, 219, 10.1016/j.jaci.2015.05.050 Saito, 2016, Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for human leukocyte antigen B (HLA-B) genotype and allopurinol dosing: 2015 update, Clin Pharmacol Ther, 99, 36, 10.1002/cpt.161 Leckband, 2013, Clinical Pharmacogenetics Implementation Consortium guidelines for HLA-B genotype and carbamazepine dosing, Clin Pharmacol Ther, 94, 324, 10.1038/clpt.2013.103 Yip, 2015, Genetics of immune-mediated adverse drug reactions: a comprehensive and clinical review, Clin Rev Allergy Immunol, 48, 165, 10.1007/s12016-014-8418-y McCormack, 2011, HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans, N Engl J Med, 364, 1134, 10.1056/NEJMoa1013297 Daly, 2009, HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin, Nat Genet, 41, 816, 10.1038/ng.379 Yuan, 2011, Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descent, AIDS (London, England), 25, 1271, 10.1097/QAD.0b013e32834779df Pavlos, 2015, T cell-mediated hypersensitivity reactions to drugs, Annu Rev Med, 66, 439, 10.1146/annurev-med-050913-022745 Chen, 2015, Genetic determinants of antithyroid drug-induced agranulocytosis by human leukocyte antigen genotyping and genome-wide association study, Nat Commun, 6, 7633, 10.1038/ncomms8633 Cheung, 2016, HLA-B*38:02:01 predicts carbimazole/methimazole-induced agranulocytosis, Clin Pharmacol Ther, 99, 555, 10.1002/cpt.309 Hallberg, 2016, Genetic variants associated with antithyroid drug-induced agranulocytosis: a genome-wide association study in a European population, Lancet Diabetes Endocrinol, 4, 507, 10.1016/S2213-8587(16)00113-3 Chung, 2014, Genetic variants associated with phenytoin-related severe cutaneous adverse reactions, JAMA, 312, 525, 10.1001/jama.2014.7859 Chen, 2014, Effects of a HLA-B*15:02 screening policy on antiepileptic drug use and severe skin reactions, Neurology, 83, 2077, 10.1212/WNL.0000000000001034 Bastuji-Garin, 2000, SCORTEN: a severity-of-illness score for toxic epidermal necrolysis, J Invest Dermatol, 115, 149, 10.1046/j.1523-1747.2000.00061.x Yang, 2014, HIV infection predisposes skin to toxic epidermal necrolysis via depletion of skin-directed CD4(+) T cells, J Am Acad Dermatol, 70, 1096, 10.1016/j.jaad.2013.12.025 Zawodniak, 2010, In vitro detection of cytotoxic T and NK cells in peripheral blood of patients with various drug-induced skin diseases, Allergy, 65, 376, 10.1111/j.1398-9995.2009.02180.x Chung, 2010, Genetic markers and danger signals in Stevens-Johnson syndrome and toxic epidermal necrolysis, Allergol Int, 59, 325, 10.2332/allergolint.10-RAI-0261 Beeler, 2008, CD69 upregulation on T cells as an in vitro marker for delayed-type drug hypersensitivity, Allergy, 63, 181 McGee, 1998, Toxic epidermal necrolysis syndrome: mortality rate reduced with early referral to regional burn center, Plast Reconstr Surg, 102, 1018, 10.1097/00006534-199809020-00014 Nigen, 2003, Drug eruptions: approaching the diagnosis of drug-induced skin diseases, J Drugs Dermatol, 2, 278 Lin, 2007, Cotrimoxazole for prophylaxis or treatment of opportunistic infections of HIV/AIDS in patients with previous history of hypersensitivity to cotrimoxazole, Cochrane Database Syst Rev, CD005646 Soares, 2015, Allopurinol desensitization: a fast or slow protocol?, J Investig Allergol Clin Immunol, 25, 295 Patterson, 2004, Pain management, Burns, 30, A10, 10.1016/j.burns.2004.08.004 Lee, 2017, Cyclosporine treatment for Stevens-Johnson syndrome/toxic epidermal necrolysis: retrospective analysis of a cohort treated in a specialized referral center, J Am Acad Dermatol, 76, 106, 10.1016/j.jaad.2016.07.048 Lehloenya, 2007, Management of Stevens Johnson syndrome and toxic epidermal necrolysis, Curr Allergy Clin Immunol, 20, 124 Samanci, 2005, Heterotopic ossification related to toxic epidermal necrolysis in a patient with Behcet's disease, J Dermatol, 32, 469, 10.1111/j.1346-8138.2005.tb00782.x Kavanagh, 1994, Silicone gel treatment of extensive hypertrophic scarring following toxic epidermal necrolysis, Br J Dermatol, 130, 540, 10.1111/j.1365-2133.1994.tb03396.x Sheridan, 2002, Long-term consequences of toxic epidermal necrolysis in children, Pediatrics, 109, 74, 10.1542/peds.109.1.74 Jullien, 1995, Eruptive nevus in the course of Lyell syndrome [in French], Ann Dermatol Venereol, 122, 540 Gueudry, 2009, Risk factors for the development of ocular complications of Stevens-Johnson syndrome and toxic epidermal necrolysis, Arch Dermatol, 145, 157 Saeed, 2016, Complications of Stevens-Johnson syndrome beyond the eye and skin, Burns, 42, 20, 10.1016/j.burns.2015.03.012 Gaultier, 2009, Severe and unrecognized dental abnormalities after drug-induced epidermal necrolysis, Arch Dermatol, 145, 1332, 10.1001/archdermatol.2009.233 Coetzer, 1998, Toxic epidermal necrolysis in a burn patient complicated by acute pancreatitis, Burns, 24, 181, 10.1016/S0305-4179(97)00107-1 Carter, 1993, Toxic epidermal necrolysis–an unusual cause of colonic perforation. Report of a case, Dis Colon Rectum, 36, 773, 10.1007/BF02048370 Herman, 1984, Esophageal stricture secondary to drug-induced toxic epidermal necrolysis, Pediatr Radiol, 14, 439, 10.1007/BF02343438 Mashiko, 2013, A case of microstomia subsequent to toxic epidermal necrolysis surgically treated by simple technique, Plast Reconstr Surg Glob Open, 1, e21, 10.1097/GOX.0b013e3182980067 Barrera, 1998, Hypopharyngeal stenosis and dysphagia complicating toxic epidermal necrolysis, Arch Otolaryngol Head Neck Surg, 124, 1375, 10.1001/archotol.124.12.1375 Rowan, 2010, Vaginal stenosis after toxic epidermal necrolysis, J Low Genit Tract Dis, 14, 390, 10.1097/LGT.0b013e3181ddf5da Jackel, 2002, Drug-induced toxic epidermal necrolysis with involvement of the intestinal and respiratory tract: a case report [in German], Anaesthesist, 51, 815 Kamada, 2006, Chronic pulmonary complications associated with toxic epidermal necrolysis: report of a severe case with anti-Ro/SS-A and a review of the published work, J Dermatol, 33, 616, 10.1111/j.1346-8138.2006.00142.x Zitha, 2014, Incidence of anxiety and depression in a predominantly HIV-infected population with severe adverse drug reactions, Clin Transl Allergy, 4, 1, 10.1186/2045-7022-4-S3-P95 Sultan, 2015, Drug reaction with eosinophilia and systemic symptoms: manifestations, treatment, and outcome in 17 patients, Int J Dermatol, 54, 537, 10.1111/ijd.12331 Ushigome, 2013, Short- and long-term outcomes of 34 patients with drug-induced hypersensitivity syndrome in a single institution, J Am Acad Dermatol, 68, 721, 10.1016/j.jaad.2012.10.017 Chen, 2013, Long-term sequelae of drug reaction with eosinophilia and systemic symptoms: a retrospective cohort study from Taiwan, J Am Acad Dermatol, 68, 459, 10.1016/j.jaad.2012.08.009 Lew, 2015, Post-traumatic stress disorder following drug reaction with eosinophilia and systemic symptoms, Br J Dermatol, 172, 836, 10.1111/bjd.13375 Lehloenya, 2012, Lichenoid drug reaction to antituberculosis drugs treated through with topical steroids and phototherapy, J Antimicrob Chemother, 67, 2535, 10.1093/jac/dks225 Funck-Brentano, 2015, Therapeutic management of DRESS: a retrospective study of 38 cases, J Am Acad Dermatol, 72, 246, 10.1016/j.jaad.2014.10.032 Galvao, 2014, Clinical and laboratory improvement after intravenous immunoglobulin in drug reaction with eosinophilia and systemic symptoms, J Allergy Clin Immunol Pract, 2, 107, 10.1016/j.jaip.2013.11.008 Marie, 2006, Intravenous immunoglobulin-associated arterial and venous thrombosis: report of a series and review of the literature, Br J Dermatol, 155, 714, 10.1111/j.1365-2133.2006.07390.x Joly, 2012, Poor benefit/risk balance of intravenous immunoglobulins in DRESS, Arch Dermatol, 148, 543, 10.1001/archderm.148.4.dlt120002-c Walsh, 2011, Drug reaction with eosinophilia and systemic symptoms (DRESS): a clinical update and review of current thinking, Clin Exp Dermatol, 36, 6, 10.1111/j.1365-2230.2010.03967.x Dube, 2013, Risk of nevirapine-associated Stevens-Johnson syndrome among HIV-infected pregnant women: the Medunsa National Pharmacovigilance Centre, 2007-2012, S Afr Med J, 103, 322 Rodriguez, 2006, Toxic epidermal necrolysis in a mother and fetus, J Am Acad Dermatol, 55, S96, 10.1016/j.jaad.2005.09.021 Knight, 2015, Stevens Johnson syndrome and toxic epidermal necrolysis: maternal and foetal outcomes in twenty-two consecutive pregnant HIV infected women, PLoS One, 10, e0135501, 10.1371/journal.pone.0135501 Struck, 2010, Toxic epidermal necrolysis in pregnancy: case report and review of the literature, J Burn Care Res, 31, 816, 10.1097/BCR.0b013e3181eed441